explore -WSS

explore

author：Wikipedia 2025-09-27 12:55:10 - browse：834

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Why depression after traumatic brain injury is distinct

WSS

First U.S. drug developed to treat liver disease MASH is approved

Trump surgeon general acknowledges mistakes during Covid

Humana sues Biden admin over Medicare Advantage audit rule

Advances in CAR

What drug price negotiations mean for Medicare Part D

Change Healthcare outage fallout shows need for new oversight

leisure time

explore

leisure time

Medical records are filled with copy

How many hemophilia patients actually want gene therapy?

BioMarin wins approval for gene therapy to treat hemophilia A

WuXi out of biotech trade group, U.S. and China relations to blame

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA advisers back CAR

Medical leaders decry Supreme Court decision on affirmative action

A rare thyroid diagnosis led to unexpected, all

BioMarin wins approval for gene therapy to treat hemophilia A

How many hemophilia patients actually want gene therapy?

hotspot

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Steward Health Care Massachusetts hospitals face fiscal disaster

How many hemophilia patients actually want gene therapy?

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

EPA limits use of carcinogenic gas for sterilizing medical devices

Trump surgeon general acknowledges mistakes during Covid

knowledge

leisure time

leisure time

leisure time